Scisparc Ltd. · NASDAQ:SPRC
Scisparc — Therapix Biosciences — Investor Presentation (April 2020)
15 slides from Scisparc's investor presentation, Apr 22, 2020
Slide 1: The Cannabinoids of the Future
THE CANNABINOIDS OF THE FUTURE
Slide 2: Disclaimer
' ISCLAIMER This presentation of Therapix Biosciences Ltd. ( the “Company”) contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects, ” “anticipates, ” “intends, ” “plans, ” “believes, ” “seeks, ” “es
Slide 3: Our Vision
OUR VISION To bridge Cannabis and cannabinoids to the healthcare system to improve the health and well - being of patients
Slide 4: Our Mission
To develop the most efficacious and safe endocannabinoid - based solutions for unmet demand for treating Inflammation and CNS Diseases OUR MISSION
Slide 5: Our Strategy
OUR STRATEGY To augment, elevate and leverage our core assets
Slide 6: Strategy Highlights
In recent years TRPX has invested millions of dollars in research and development of cannabinoid based products for the treatment of several indications, with a large unmet need, including: Tourette - Syndrome, Autism Spectrum Disorder (ASD), Obstructive Sleep Apnea, pain and anti - infection & infl
Slide 7: Cannabinoid Entourage Platform
Cannabinoid Entourage Platform Micro Dosing Proprietary formulations New chemical entities (NCE's ) Proprietary Assets 9 Patents Families
Slide 8: The endogenous cannabinoid system is involved in essentially every disease
The endogenous cannabinoid system is involved in essentially every disease that has been investigated Professor Raphael Mechoulam • Scientific research since the 1960 ’s shows that the key to unlocking many medical conditions and chronic diseases lies in the Endocannabinoid System ( eCB ) • Endocann
Slide 9: Dose Matters
Dosage regiment compromises therapeutic benefits of cannabis and severely impacts treatment DOSE MATTERS x Serious diminishing effect over time and extensive use x High doses lead to unwanted adverse events x Compromises therapeutic benefits of cannabis and severely impacts treatment REDUCING MEDICA
Slide 10: The Entourage Therapeutic Potential
The Entourage Therapeutic Potential Harnessing the therapeutic potential of cannabinoids by improving efficacy and minimizing psychological side effects
Slide 11: Business Plan: THX Platform, The Entourage Effect
11 Business Plan THX Platform: The Entourage Effect Platform Therapix’ proprietary combination of Cannabinoids and CannAmide™ (“Entourage Effect”), is intended for the increased efficiency, lowering the dosage and side effects IP CannAmide™ 400 mg Production GMP production of the APIs: Rigorously co
Slide 12: Pipeline
COMPOUND THX – 110 THERAPEUTIC AREA PRECLINICAL Medical Cannabis route PHASE IIa PHASE IIb TOURETTE’S SYNDROME OBSTRUCTIVE SLEEP APNEA THX – 110 THX – 210 Autism THX – 160 Pain THX - 110 – Full Cannabis Extract (FCE) with CannAmide TM for the treatment Tourette’s Syndrome and Obstructive Sleep Apnea
Slide 13: Leadership & Scientific Advisory Board
Leadership & Scientific Advisory Board 21
Slide 14: Leadership
DR. ASCHER SHMULEWITZ, MD PHD, CHAIRMAN An inventor, investor and serial entrepreneur in biomedical technologies, he has founded and invested in over two dozen life science companies including NeoVision Corp, Labcoat Medical Ltd. Arteria Corp, Circulation Inc. and X - Cardia Inc., and has led multip
Slide 15: Therapix Biosciences Scientific Advisory Board
Therapix Biosciences Scientific Advisory Board Award winning, active scientists CNS Endocannabinoids and PEA PAIN Dr. Michael Bloch Prof. James Leckman Prof. Raphael Mechoulam Prof. Avi Weizman Prof. Kirsten Muller - Vahl Prof. Michael Davidson Prof. Elon Eisenberg Dr. Daniele Piomelli Prof. Saoirse
Therapix Biosciences — Investor Presentation (April 2020) on 6ix